A Complete List of GLP-1 Medications in 2026
Every FDA-approved GLP-1 receptor agonist and dual agonist listed with brand names, dosing, approved indications, and key clinical data.
The GLP-1 medication landscape has expanded rapidly. This guide covers every approved GLP-1 receptor agonist and related medication, plus key drugs in the pipeline.
FDA-Approved GLP-1 Receptor Agonists
Semaglutide
| Brand | Form | Dose | Indication | Approval Year |
|---|---|---|---|---|
| Ozempic | Injection (weekly) | 0.25-2.0mg | Type 2 diabetes | 2017 |
| Rybelsus | Oral tablet (daily) | 3-14mg | Type 2 diabetes | 2019 |
| Wegovy | Injection (weekly) | 0.25-2.4mg | Chronic weight management | 2021 |
Semaglutide is the most widely studied GLP-1 RA. Manufactured by Novo Nordisk, it has been tested in the SUSTAIN (diabetes), STEP (weight loss), PIONEER (oral), and SELECT (cardiovascular) trial programmes.
Tirzepatide (Dual GIP/GLP-1 Agonist)
| Brand | Form | Dose | Indication | Approval Year |
|---|---|---|---|---|
| Mounjaro | Injection (weekly) | 2.5-15mg | Type 2 diabetes | 2022 |
| Zepbound | Injection (weekly) | 2.5-15mg | Chronic weight management | 2023 |
Manufactured by Eli Lilly. Tirzepatide activates both GLP-1 and GIP receptors. For a detailed comparison with semaglutide, see our tirzepatide vs semaglutide guide.
Liraglutide
| Brand | Form | Dose | Indication | Approval Year |
|---|---|---|---|---|
| Victoza | Injection (daily) | 0.6-1.8mg | Type 2 diabetes | 2010 |
| Saxenda | Injection (daily) | 0.6-3.0mg | Chronic weight management | 2014 |
Manufactured by Novo Nordisk. Liraglutide was the first GLP-1 RA approved for weight loss. It requires daily injections, which is less convenient than weekly options.
Dulaglutide
| Brand | Form | Dose | Indication | Approval Year |
|---|---|---|---|---|
| Trulicity | Injection (weekly) | 0.75-4.5mg | Type 2 diabetes | 2014 |
Manufactured by Eli Lilly. The REWIND trial showed cardiovascular benefits in patients with diabetes.
Exenatide
| Brand | Form | Dose | Indication | Approval Year |
|---|---|---|---|---|
| Byetta | Injection (twice daily) | 5-10mcg | Type 2 diabetes | 2005 |
| Bydureon | Injection (weekly) | 2mg | Type 2 diabetes | 2012 |
Manufactured by AstraZeneca. Exenatide was the first GLP-1 RA approved (2005) and is based on a compound found in Gila monster saliva.
Lixisenatide
| Brand | Form | Dose | Indication | Approval Year |
|---|---|---|---|---|
| Adlyxin | Injection (daily) | 10-20mcg | Type 2 diabetes | 2016 |
Manufactured by Sanofi. Less commonly prescribed than other options.
Albiglutide (Discontinued)
Tanzeum was a weekly GLP-1 RA by GlaxoSmithKline, withdrawn from market in 2018 for commercial reasons, not safety concerns.
Combination Medications
| Brand | Components | Form | Indication |
|---|---|---|---|
| Soliqua | Lixisenatide + insulin glargine | Daily injection | Type 2 diabetes |
| Xultophy | Liraglutide + insulin degludec | Daily injection | Type 2 diabetes |
Key Drugs in the Pipeline
Retatrutide (Triple Agonist)
A GLP-1/GIP/glucagon triple receptor agonist by Eli Lilly. Phase 2 results showed up to 24.2% weight loss at 48 weeks (Jastreboff et al., 2023, NEJM). Phase 3 trials are ongoing. Read more in our retatrutide guide.
Orforglipron (Oral Non-Peptide GLP-1)
An oral small-molecule GLP-1 RA by Eli Lilly. Phase 2 showed up to 14.7% weight loss over 36 weeks without the fasting restrictions of oral semaglutide. Phase 3 trials (ATTAIN) are underway.
Survodutide (Dual GLP-1/Glucagon)
A dual GLP-1/glucagon agonist by Boehringer Ingelheim showing promise for both weight loss and NASH/MASH (fatty liver disease). Phase 3 trials ongoing.
Pemvidutide
A dual GLP-1/glucagon agonist by Altimmune, also in clinical development for weight loss and liver disease.
How to Choose the Right GLP-1 Medication
Consider these factors with your doctor:
- Primary goal - Weight loss? Diabetes management? Cardiovascular protection?
- Dosing preference - Weekly injection, daily injection, or oral pill?
- Insurance coverage - Check your formulary for covered options
- Cost - See our GLP-1 cost guide
- Side effect tolerance - See our side effects guide
- Efficacy goals - For maximum weight loss, see best GLP-1 for weight loss
The Bottom Line
The GLP-1 medication class has grown from a single diabetes drug (exenatide, 2005) to a diverse family of treatments addressing diabetes, obesity, cardiovascular disease, and potentially more. New formulations, dual and triple agonists, and oral options continue to expand the choices available. Your healthcare provider can help you navigate the options based on your specific needs.
Track your GLP-1 medication with GLP Pal.